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http://dx.doi.org/10.1016/j.kjms.201Abstract Duodenal adenocarcinoma is a rare cancer, contributing <10 % of periampullary
carcinoma. This study reviews the single center experience of duodenal adenocarcinoma
and analyzes the clinical and pathological factors to predict survival and recurrence. The re-
cords of 50 patients with duodenal adenocarcinoma who underwent surgical exploration or
resection from 1995 to 2010 were reviewed retrospectively. Univariate and multivariate ana-
lyses were performed to identify the clinicopathological factors associated with survival and
recurrence. There were 35 men and 15 women, with a mean age of 61 years. In multivariate
analysis of 50 patients, R0 resection [p Z 0.041, hazard ratio (HR) Z 3.569, 95% confidence
interval (CI) Z 1.057e12.054] and symptom at initial admission (p Z 0.025, HR Z 11.210,
95% CI Z 1.354e92.812) were independent prognostic factors for overall survival. Thirty-six
patients underwent curative resection (resectability 72%). The 5-year survival rates for cura-
tive and noncurative resections were 46.4% and 0%, respectively. Univariate analysis of 36 pa-
tients who underwent R0 resection revealed that symptoms at initial admission (p Z 0.023),
presence of lymph node metastasis (pZ 0.034), and perineural invasion (pZ 0.025) were sig-
nificant prognostic factors after curative resection. There was no significant factor for overall
survival in the multivariate analysis. There was recurrence in 15 patients, mainly as liver
metastasis. Multivariate analysis revealed that presence of symptom (p Z 0.047,
HR Z 5.362, 95% CI Z 1.021e28.149) and ulcerative tumor (p Z 0.036, HR Z 5.668, 95%
CIZ 1.123e28.619) were independent factors for disease free survival. An aggressive surgical
approach to achieve R0 resection was important to enhance survival. Most of the recurrence
occurred within 1 year after surgery. Close follow-up is necessary after surgical resection.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.eclare no conflicts of interest.
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Duodenal adenocarcinoma is a rare neoplasm that com-
prises <0.5% of all gastrointestinal malignancies [1e3].
These neoplasms are usually grouped as periampullary
carcinoma because most tumors arise in the periampullary
region [3]. It is the least common, and accounts for 6% of
periampullary tumors [3,4]. Because the incidence of
duodenal cancer is low, most studies have been performed
retrospectively with relatively few patients and a longer
period of inclusion than other periampullary malignancies.
Therefore, several points such as the extent of surgery
including the extent of lymph node dissection and prog-
nostic pathological factors are still controversial [1,3,5e7].
Duodenal adenocarcinoma is usually diagnosed late,
because symptoms are nonspecific and resemble those of
duodenal ulcer [8,9]. The surgical procedure for duodenal
adenocarcinoma varies and usually depends on the location
of the tumor. Segmental resection of the duodenum or
pancreaticoduodenectomy is performed most commonly.
Several clinicopathological factors have been reported
to affect survival for primary duodenal adenocarcinoma
[1,3,5e7]. The aim of this study was to investigate the
survival outcome of patients with primary duodenal
adenocarcinoma and the prognostic factors affecting sur-
vival and recurrence.
Methods
From January 1995 to December 2010, 50 patients were
treated for primary adenocarcinoma of duodenum at the
Department of Surgery, Korea University Medical Center,
Seoul, Korea. Of these patients, 36 (72%) underwent R0
resection and 14 (28%) received bypass surgery without
resection (R2). We included duodenal adenocarcinoma and
excluded papilla of Vater cancer.
The following demographics and clinicopathological in-
formation were reviewed retrospectively from the medical
records: age, sex, comorbidities, symptoms and signs,
preoperative diagnostic investigation, American Society of
Anesthesiologists (ASA) class (http://www.asahq.org/
clinical/physicalstatus.htm), operative procedures and
time, postoperative complication, pathological results,
adjuvant therapy, occurrence, and mode of recurrence.
Pathologically, the macroscopic tumor diameter was
evaluated. The gross morphological features were classified
into two categories: noninfiltrative versus infiltrative and
nonulcerative versus ulcerative. The microscopic features
investigated were differentiation, presence of perineural
invasion, lymphatic invasion, lymph node metastasis, and
margin status. Tumor stage was defined according to the 7th
edition of pathological tumor node metastasis (pTNM)
classification proposed by the American Joint Committee
on Cancer (AJCC) [10]. According to the classification, T1
tumors invade the lamina propria, muscularis mucosae, or
submucosa; T2 tumors invade the muscularis propria; T3
tumors invade subserosa or nonperitonealized perimuscular
tissue with extension of <2 cm and T4 tumors perforate the
visceral peritoneum or directly invade other organs or
structures (mesentery or retroperitoneum exceeding 2 cm),
and the abdominal wall or invade the pancreas. N1 diseasedemonstrates metastasis in one to three regional lymph
nodes and N2 denotes metastasis in four or more regional
lymph nodes. The regional lymph nodes for the duodenum
are the pancreaticoduodenal, pyloric, hepatic, and supe-
rior mesenteric nodes.
The location of the tumor was designated according to its
location in the first portion of the duodenum (D1), second
portion (D2), third portion (D3), and fourth portion (D4). If
the tumor involves two or more portions of the duodenum,
each portion of duodenum is expressed together as follows:
D12 involves the first and second portions of the duodenum,
D23 involves the second and third portions, and so on. Pa-
tients who received R0 resection were classified into two
groups according to the location of the tumor: D1 involved
tumor versus non-D1 involved tumor, and D2 involved tumor
versus non-D2 involved tumor.
Patients were followed-up at 1e2 weeks after discharge
and every 3e6 months thereafter. Follow-up for duodenal
cancer patients consisted of laboratory tests and imaging,
such as abdominal ultrasonography and/or computed to-
mography (CT). Abdominal CT scan has become the main
diagnostic tool for the detection of recurrence. Patients
were also evaluated when recurrence was suspected.
Data are expressed as the mean  standard deviation
or median with 25th percentile and 75th percentile for
continuous variables. Statistical analysis was performed
using SPSS, version 13.0 for Windows (SPSS Inc., Chicago, IL,
USA). Survival was measured from the date of operation.
Follow-up of patients was completed when death occurred
or until August 31, 2012. Disease-free survival (DFS) was
measured from the date of surgery to diagnosis of recur-
rence. Survival was calculated by the KaplaneMeier
method. Clinicopathological factors were analyzed by the
univariate KaplaneMeier method and compared by the log-
rank test to identify significant prognostic predictors for
overall survival and DFS. Multivariate analysis using the Cox
proportional hazards model was performed to identify the
independent prognostic predictors for overall survival.
Comparisons between groups were tested using the Pearson
Chi-square test. A p value <0.05 was considered statisti-
cally significant.
Results
Clinical characteristics
The patients comprised 35 men and 15 women with a mean
age of 61 years (range, 38e82 years). The chief complaint
at admission was abdominal pain (n Z 21), vomiting
(n Z 9), gastrointestinal bleeding (n Z 8), dyspepsia
(n Z 8), weight loss (n Z 5), jaundice (n Z 3), diarrhea
(nZ 1), and edema (nZ 1). Seven patients were diagnosed
as duodenal cancer asymptomatically by general medical
check-up. All patients were suspected duodenal cancer
preoperatively. Of the 50 patients, 48 received esoph-
agogastroscopy, which was diagnostic of duodenal cancer in
45 patients. Endoscopic biopsy was performed in 47 pa-
tients. The results were adenocarcinoma (n Z 29), ade-
noma (n Z 5), inflammation (n Z 7), and atypical cell or
dysplasia (n Z 5). CT scans were acquired in 47 patients
and were diagnostic of duodenal cancer in 32 patients.
Table 2 Univariate analysis of prognostic factors for
overall survival in 50 patients with duodenal cancer.
Prognostic factors No. of
patients
5YSR
(%)
p
Curativity R0 36 46.4 <0.001
R2 14 0
Age (y) <60 22 45.8 0.145
60 28 17.6
Sex M 35 30.5 0.797
F 15 36.9
Symptom Asymptomatic 7 80 0.012
Symptomatic 43 23.9
Hyperbilirubinemia No 42 37.2 0.020
Yes 8 0
Anemia No 33 39.5 0.127
Yes 17 18.1
ASA class I 9 66.7 <0.001
II 36 23.0
III 5 0
T stagea T1,T2,T3 10 85.7 0.026
T4 35 26.9
TNM stageb I 7 55.6 0.001
II 16 48.8
III 18 25.6
IV 8 0
Adjuvant therapy No 29 18 0.046
Yes 21 49.2
5YSR Z 5-year survival rate; ASA Z American Society of Anes-
thesiologists; TNM Z tumor node metastasis.
a Five patients had unknown T stage due to bypass surgery.
b One patient received laparoscopic gastrojejunostomy due to
severe comorbidity and old age, therefore exact stage was
unknown.
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(n Z 9), ASA 2(n Z 36), and ASA 3 (n Z 5). Of the 50 pa-
tients, 36 received curative resection (resectability 72%).
The operative procedure according to the location of tumor
is summarized in Table 1. The main procedure was pan-
creaticoduodenectomy, classic Whipple’s operation in 18
patients and pylorus-preserving pancreaticoduodenectomy
in 13 patients. The choice of operation was determined
according to the location of the tumor. Combined resection
of other organs was performed in nine patients and involved
right hemicolectomy (n Z 3), segmental resection of
transverse colon (n Z 2), liver resection (n Z 1), radical
cholecystectomy (n Z 1), and portal vein resection and
anastomosis (n Z 2). The mean operation time was 367
minutes for curative resection. Fourteen patients received
R2 resection (bypass surgery for palliation in 13 patients
and exploration in 1 patient) due to a locally advanced and
unresectable tumor (n Z 9), peritoneal seeding (n Z 4),
and distant metastasis (n Z 6).
Postoperative complications occurred in 22 patients
(morbidity 44%), which most commonly was intra-
abdominal abscess (n Z 14) associated with postoperative
pancreatic fistula in pancreaticoduodenectomy. Other
complications were pulmonary complications (n Z 6),
bleeding (n Z 4), delayed gastric emptying (n Z 3), su-
perficial surgical site infection (n Z 3), and congestive
heart failure (n Z 1). Postoperative mortality occurred in
three patients whose causes of death were septic shock
after curative surgery (n Z 2) and exacerbation of under-
lying congestive heart failure (n Z 1) after laparoscopic
gastrojejunostomy for palliation, representing an overall
mortality rate of 6%.
Adjuvant chemotherapy was performed in 21 patients,
usually based on 5-fluoruracil monotherapy or 5-fluorouracil
combined with cisplatin.
Overall survival and clinicopathological factors
affecting survival
Of the 50 patients with duodenal carcinoma, the overall
survival rate was 38.8% at 3 years and 32.3% at 5 years, with a
median survival time of 24.4 months. R0 resection
(p < 0.001), symptom at initial admission (p Z 0.012),
hyperbilirubinemia (p Z 0.020), ASA class (p < 0.001), TTable 1 Operative procedures according to the location
of tumor.
D1 D2 D3 D12 D23 D34 Total
PD 4 9 1 2 2 18
PPPD 1 10 2 13
Transduodenal
excision
1 1
Segmental
resection
1 1 2
SGD 2 2
Total 7 20 2 2 4 1 36
PD Z pancreaticoduodenectomy; PPPD Z pylorus-preserving
pancreaticoduodenectomy; SGD Z subtotal gastrectomy with
segmental resection of duodenum.
Figure 1. The overall survival was significantly different
according to R status (p < 0.001). Five-year survival of R0
resection group was 46.4%, and R2 resection group was 0%.
Surgical outcome of duodenal cancer 257stage (p Z 0.026), TNM stage (p Z 0.001), and adjuvant
chemotherapy (p Z 0.046) were significant factors for
overall survival rate in the univariate analysis (Table 2). In
multivariate analysis, R0 resection [pZ 0.041, hazard ratio
(HR)Z 3.569, 95% confidence interval (CI)Z 1.057e12.054]
and symptom at initial admission (pZ 0.025, HRZ 11.210,
95% CI Z 1.354e92.812) were independent prognostic fac-
tors for overall survival.
Of the 36 patients who underwent R0 resection, the
overall survival rate was 46.4% at 5 years (Fig. 1). Symptom
at initial admission (p Z 0.023), perineural invasion
(p Z 0.025), and lymph node metastasis (p Z 0.034) were
significant prognostic factors for overall survival in univar-
iate analysis. Ulceration and infiltration of tumor, differ-
entiation, location of tumor, T stage, and TNM stage did
not affect overall survival significantly (Table 3). However,
in multivariate analysis, there was no significantlyTable 3 Univariate analysis of prognostic factors for overall su
resection.
Prognostic factors
Age (y) <60
60
Sex M
F
Symptom Asymptomatic
Symptomatic
Hyperbilirubinemia No
Yes
Anemia No
Yes
ASA class I
II
Size of tumor (cm) 3
>3
Ulceration of tumor Nonulcerative
Ulcerative
Infiltration of tumor Noninfiltrative
Infiltrative
Differentiation Well
Moderate and poor
Lymphatic invasion No
Yes
Perineural invasion No
Yes
Lymph node metastasis No
Yes
Involvement of D1 No
Yes
Involvement of D2 No
Yes
T stage T1,T2,T3
T4
TNM stage I
II
III
Adjuvant therapy No
Yes
5YSR Z 5-year survival rate; ASA Z American Society of Anesthesioloindependent prognostic factor for overall survival after
curative resection.Recurrence and clinicopathological factors
affecting disease-free survival
Recurrence after curative resection of duodenal cancer was
detected in 15 patients. Fourteen patients did not
demonstrate recurrent disease during the follow-up period,
and the status of eight patients was unknown. The site of
recurrence was locoregional in three patients, liver
metastasis in 10 patients, lymph node metastasis in five
patients, and peritoneal seeding in three patients. Only one
patient showed solitary locoregional recurrence. Treat-
ments for recurrent disease was performed in 10 patients,
and were systemic chemotherapy (n Z 6), concurrentrvival in 36 patients with duodenal cancer who received R0
No. of patients 5YSR (%) p
16 62.5 0.251
20 25.7
25 45.4 0.742
11 48.6
6 100 0.023
30 35.3
31 51.4 0.111
5 0
26 51.3 0.45
10 33.3
8 75 0.136
28 31.7
15 45.7 0.535
21 46.5
17 59.7 0.576
19 35.5
19 62.5 0.084
17 23.9
11 64.6 0.125
25 38.5
29 48.4 0.062
7 40
26 55.5 0.025
10 18.5
21 60.8 0.034
15 27.8
27 45.6 0.810
9 50
10 66.7 0.273
26 34.9
10 85.7 0.071
26 36.0
7 55.6 0.082
16 57.1
13 28.6
18 27 0.386
18 62.3
gists; TNM Z tumor node metastasis.
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metastatic liver tumor (n Z 1).
The overall DFS rates were 60.3% at 1 year and 31.3% at 3
years. Median DFS time was 15.4 months and 10 patients
demonstrated recurrence within 1 year after curative
resection. Univariate analysis of clinicopathological pre-
dictors for DFS showed that presence of symptom at initial
admission (p Z 0.045) was a significant factor; however,
lymph node metastasis (pZ 0.052) demonstrated poor DFS
with marginal significance. In multivariate analysis, the
presence of symptom (p Z 0.047, HR 5.362, 95% CI
1.021e28.149) and ulcerative tumor (p Z 0.036, HR 5.668,
95% CI 1.123e28.619) were independent factors for DFS.Discussion
In the current study, duodenal adenocarcinoma was diag-
nosed at an advanced stage. More than two-thirds of pa-
tients who underwent curative resection were categorized
as T4. To achieve R0 resection, pancreaticoduodenectomy
with a combined operation involving the cancer-invaded
organ was performed frequently. Survival was significantly
improved for patients who underwent curative resection
rather than palliative surgery. The resectability rate has
been reported as 53e67%. Performance of curative resec-
tion is the strongest determinant of outcome [3,7,11]. An
aggressive surgical approach to achieve complete tumor
removal should be performed.
The diagnostic rate seemed to be low at the preopera-
tive stage: endoscopically proven malignancy was 29 among
47 patients, and there were 32 suspected duodenal cancers
among 47 patients who had CT scans in the current study. If
malignancy was suspected, but not proven by endoscopic
biopsy or CT preoperatively, surgical exploration with
intraoperative frozen biopsy could be an option. In those
cases, malignancy favored extensive curative resection and
bypass surgery for benign stricture, and limited surgical
resection with free margin of tumor could be performed in
the case of adenoma.
Lymph node metastasis is one of the most significant
prognostic factors in duodenal carcinoma [1,5e7], and was
also apparent in the present study. The risk of lymph node
metastasis increases with T stage, and 5-year survival de-
creases as the number of metastatic lymph nodes in-
creases, which seems to be significantly poorer when more
than four lymph nodes are metastasized or more than 20%
of the retrieved nodes are invaded by tumors [6]. Other
authors have reported that the presence of lymph node
metastasis is not a significant prognostic factor and the
location of the involved nodes does not influence outcome
[3,5,11,12]. Therefore, they emphasized the aggressive
surgical role to enhance survival outcome, although lymph
node metastasis was present.
Prognostic factors, such as weight loss, surgical type,
tumor location, presence of perineural invasion, resection
margin status, and tumor grade and stage, remain
controversial in terms of whether or not they might
impact on survival in the review of literature
[1,3,5,6,8,11e13]. In the current study, presence of
symptom and ulcerative tumor were independent factors
for DFS rather than factors associated with tumor stage.This might be because the number of patients included in
this study was small and most of the patients were T4 (26
patients/36 patients), and most were TNM stage II or III.
Therefore, pathological factors including stage were not a
significant factor for disease free survival in the multi-
variate analysis.
Duodenal adenocarcinoma seems to be more biologically
comparable to gastric cancer rather than pancreatic
adenocarcinoma [11]. The choice of procedure was deter-
mined according to the location of the tumor. Usually,
segmental resection is appropriate for patients with lesions
of the distal duodenum. For D1 and D2 lesions, pan-
creaticoduodenectomy is required [1]. No difference has
been found in the survival rates between patients under-
going segmental resection and pancreaticoduodenectomy
[1,5]. However, other authors have reported a survival
difference according to the operative procedure. Pan-
creaticoduodenectomy was more beneficial to overall sur-
vival than pancreas-sparing duodenectomy, and D1 and D2
tumors demonstrated better survival than D3 and D4 tu-
mors [3].
Recent studies have reported that adjuvant chemo-
radiotherapy does not decrease local recurrence or prolong
overall survival [1,2,6]. However, adjuvant chemoradiation
therapy is used more commonly for patients with nodal
metastasis [6], and might enhance locoregional control in
the advanced stage of duodenal cancer following curative
resection [2]. The pattern of recurrence after curative
resection is mainly distant, and the most common site of
distant metastasis is the liver [1,6,13]. Although presently
locoregional control of duodenal adenocarcinoma could be
achieved most often by pancreaticoduodenectomy and
combined operation involving the invaded organ, systemic
control to prevent disease progression remains to be
solved. In the current study, adjuvant chemotherapy did
not affect overall survival and DFS following curative
resection. However, systemic chemotherapy was effective
in improving survival outcome after curative or palliative
surgery. Because most studies have been performed on
retrospectively with a relatively small number of patients,
and adjuvant chemotherapy tends to be delivered in
advanced cases [6], the chemotherapeutic agent and
regimen were not homogeneous. Further studies will be
necessary to investigate the role of adjuvant chemo- and/
or radiotherapy to achieve systemic as well as locoregional
control of duodenal adenocarcinoma in a prospective clin-
ical trial.
In conclusion, duodenal adenocarcinoma was diagnosed
at an advanced stage, and the resectability was low.
Curative resection enhanced survival, indicating that a
vigorous surgical approach with combined resection of the
invaded organ should be pursued. Lymph node metastasis
was a significant prognostic factor affecting survival.
Recurrence was diagnosed within 1 year after curative
resection in two-thirds of the recurrent patients, mainly as
distant metastasis. Therefore, a careful follow-up program
with short-term interval should be applied and adjuvant
chemoradiotherapy might be considered in an advanced
disease, although the impact of adjuvant therapy affecting
survival was not obvious. Further studies will be necessary
to investigate the effect of adjuvant therapy for duodenal
adenocarcinoma in a prospective clinical trial.
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